Reimagining Respiratory Protection

Why this Challenge matters

Johnson＆Johnson Innovation一直致力于全球大流行准备工作，这是当今世界上为数不多的创新医疗保健公司之一，这些公司在多种疾病领域和方法中积极参与这一挑战至关重要。

2016年联合国reportconcluded that, “The world remains ill-prepared to address the threat posed by epidemics,” urging action ahead of future pandemics to avoid devastating consequences. Epidemics are not only possible, but probable, with four in recent memory including the Ebola virus in West Africa. The same UN study points to mathematical modelling by the Bill and Melinda Gates Foundation which shows that a virulent strain of an airborne influenza virus could spread to all major global capitals within 60 days and kill more than 33 million people within 250 days.

传统的呼吸保护装置设计用于职业环境，并且对于全球采用而言非常昂贵。一次性版本（例如N95呼吸器）仅适用于成人，必须进行调查以确保正常工作，并且穿着不舒服[1]。

Just how big of a problem is this? Given an outbreak of a novel or newly emerging respiratory disease, respiratory protection may be a crucial measure to protect healthcare workers and the general public. Yet, demand for such products in influenza or other respiratory disease pandemic would far exceed worldwide supply.

Yet, decades have passed without a significant change to design.Together, we have the power to prevent needless suffering and start saving more lives by improving respiratory safety for everyone around the world.

--------------------------------------------------------------

[1]《职业与环境卫生杂志》第9卷，2012年 - 第1期，与长期呼吸保护相关的不适和劳累环境中：2011年12月14日在线访问：https://www.tandfonline.com/doi/abs/10.1080/15459624.2012.635133

What we’re looking for

包含的建议or describing a path forward to meet any ofthe following criteria are preferred, but are not required.Please keep in mind that no idea is too big or too early for consideration.Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation. The ideal respiratory protection would have the following characteristics:

• Suitable for all populations and ages
• 有效预防感染
• 舒服的
• 可重复使用至少5次或极低的成本，易于生产
• Simple, requires no special instructions or fit testing
• 最少干扰呼吸或其他活动

Application process

Applicants will be required to submit a design. Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

• Novelty
• Potential Impact
• Feasibility/Practicality
• 团队和资源的质量
• Plan for use of funds
• Clarity of plan: Milestones & defined go/no go decisions

About BARDA

Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA supports the transition of medical countermeasures such as vaccines, drugs, and diagnostics from research through advanced development towards consideration for approval by the FDA and inclusion into the Strategic National Stockpile. BARDA’s support includes funding, technical assistance and core services. To date, BARDA has supported 42 FDA approvals for 38 unique products addressing CBRN, PI, and EID threats.

我们的使命是通过与行业成功的公私合作伙伴关系来实现的，以共享风险，提高效率并加速发展，同时维持市场，以保证继续使用疫苗，治疗剂，诊断和其他对我们国家健康安全至关重要的医疗产品。有关巴达的更多信息，请访问https://www.phe.gov/about/barda或关注@barda，@phegov。

About the Janssen Pharmaceutical, Companies of Johnson & Johnson

詹森制药公司的约翰逊& Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

关于约翰逊和约翰逊Innovation

ld乐动Johnson＆Johnson Innovation LLC致力于加快全球创新的所有阶段，并在企业家和Johnson＆Johnson的全球医疗保健业务之间建立合作。Johnson＆Johnson Innovation为科学家，企业家和新兴公司提供一站式访问科学和技术专家，他们可以促进约翰逊和约翰逊的药品，医疗设备和消费者公司的合作。在Johnson＆Johnson的创新伞下，我们通过区域创新中心与创新者联系；约翰逊和约翰逊创新|JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation,
请拜访：www.jnjinnovation.com。

关于约翰逊和约翰逊Innovation, JLABS

约翰逊和约翰逊创新|JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visitwww.www.2574design.comor follow @JLABS.

关于约翰逊和约翰逊

在Johnson＆Johnson，我们认为身体健康是充满活力的生活，蓬勃发展的社区和前进进步的基础。这就是为什么130多年来，我们的目标是在每个年龄阶段和生活的每个阶段保持良好的状态。如今，作为世界上最大，最广泛的医疗保健公司，我们致力于永远利用自己的覆盖范围和规模。我们努力提高获得和负担能力，建立更健康的社区，并在各地的每个人身上触及健康的身体，身体和环境。我们将心脏，科学和创造力融合在一起，深刻地改变了人类健康的轨迹。